Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001914
Filing Date
2024-11-13
Accepted
2024-11-13 07:15:34
Documents
89
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20240930x10q.htm   iXBRL 10-Q 2044787
2 EX-31.1 tmb-20240930xex31d1.htm EX-31.1 12019
3 EX-31.2 tmb-20240930xex31d2.htm EX-31.2 11889
4 EX-32.1 tmb-20240930xex32d1.htm EX-32.1 7529
  Complete submission text file 0001410578-24-001914.txt   9967495

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20240930.xsd EX-101.SCH 80630
6 EX-101.CAL tmb-20240930_cal.xml EX-101.CAL 68026
7 EX-101.DEF tmb-20240930_def.xml EX-101.DEF 347266
8 EX-101.LAB tmb-20240930_lab.xml EX-101.LAB 698208
9 EX-101.PRE tmb-20240930_pre.xml EX-101.PRE 524347
92 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240930x10q_htm.xml XML 1645452
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
Entero Therapeutics, Inc. (Filer) CIK: 0001604191 (see all company filings)

EIN.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37853 | Film No.: 241451163
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)